Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kazuhito Nii is active.

Publication


Featured researches published by Kazuhito Nii.


The American Journal of Surgical Pathology | 2017

Tumor Spread Through Air Spaces Is an Independent Predictor of Recurrence-free Survival in Patients With Resected Lung Squamous Cell Carcinoma

Kyuichi Kadota; Yoshio Kushida; Naomi Katsuki; Ryou Ishikawa; Emi Ibuki; Mutsumi Motoyama; Kazuhito Nii; Hiroyasu Yokomise; Shuji Bandoh; Reiji Haba

Tumor spread through air spaces (STAS) is a newly recognized pattern of invasion in lung adenocarcinoma. However, clinical significance of STAS has not yet been characterized in lung squamous cell carcinoma. In this study, we investigated whether STAS could determine clinical outcome in Japanese patients with lung squamous cell carcinoma. We reviewed tumor slides from surgically resected lung squamous cell carcinomas (n=216). STAS was defined as tumor cells within air spaces in the lung parenchyma beyond the edge of the main tumor. Tumors were evaluated for histologic subtypes, tumor budding, and nuclear diameter. Recurrence-free survival (RFS) was analyzed using the log-rank test and the Cox proportional hazards model. Tumor STAS was observed in 87 patients (40%), increasing incidence with lymph node metastasis (P=0.037), higher pathologic stage (P=0.026), and lymphatic invasion (P=0.033). All cases with STAS showed a solid nest pattern. The 5-year RFS for patients with STAS was significantly lower than it was for patients without STAS in all patients (P=0.001) and in stage I patients (n=134; P=0.041). On multivariate analysis, STAS was an independent prognostic factor of a worse RFS (hazard ratio=1.61; P=0.023). Patients with STAS had a significantly increased risk of developing locoregional and distant recurrences (P=0.012 and 0.001, respectively). We found that tumor STAS was an independent predictor of RFS in patients with resected lung squamous cell carcinoma, and it was associated with aggressive tumor behavior.


European Journal of Cancer | 2015

Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells

Yoshimasa Tokunaga; Dage Liu; Jun Nakano; Xia Zhang; Kazuhito Nii; Tetsuhiko Go; Cheng-long Huang; Hiroyasu Yokomise

BACKGROUND Ribonucleotide reductase large subunit (RRM1) is the main enzyme responsible for synthesis of the deoxyribonucleotides used during DNA synthesis. It is also a cellular target for gemcitabine (GEM). Overexpression of RRM1 is reportedly associated with resistance to GEM and the poor prognosis for many types of malignant tumours. Aim of the present study is to establish gene therapy against RRM1-overexpressing tumours. METHOD An adenoviral vector that encoded a short hairpin siRNA targeting the RRM1 gene (Ad-shRRM1) was constructed. Two RRM1-overexpressing non-small cell lung cancer (NSCLC) lines, MAC10 and RERF-LC-MA, were used. Finally, a human tumour xenograft model in nude mice was prepared by subcutaneously implanting tumours derived from RERF-LC-MA cells. RESULTS Ad-shRRM1 effectively downregulated RRM1 mRNA and protein in both types of NSCLC cells and significantly reduced the percentage of viable cells as detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (p<0.005). Caspase 3/7 analysis revealed that transfection with Ad-RRM1 increased the percentage of apoptotic cells in culture containing either type of RRM1-overexpressing cell (p<0.001). Treatment with Ad-shRRM1 exerted a potent antitumour effect against the RRM1-overexpressing RERF-LC-MA xenografts (p<0.05). Furthermore, Ad-shRRM1-mediated inhibition of RRM1 specifically increased sensitivity to gemcitabine of each type of RRM1-overexpressing tumour cell. Combination treatment with Ad-shRRM1 and GEM exerted significantly greater inhibition on cell proliferation than Ad-shRRM1 or GEM treatment alone. CONCLUSION RRM1 appeared to be a promising target for gene therapy, and Ad-shRRM1 had strong antitumour effects, specifically anti-proliferative and pro-apoptotic effects, against NSCLC cells that overexpressed RRM1. Combination therapy with Ad-shRRM1 and GEM may become a new treatment option for patients with NSCLC.


Surgical Case Reports | 2017

Spontaneous torsion of the right upper lung lobe: a case report

Yusuke Kita; Tetsuhiko Go; Kazuhito Nii; Hiroyasu Yokomise

BackgroundPulmonary torsion is usually caused by thoracic surgery or trauma. Spontaneous pulmonary torsion caused by tumor and pleural effusion is very rare.Case presentationA 76-year-old Asian male with a chronic cough and suspected lung or pleural tumor presented with sudden dyspnea. Computed tomography showed that the right upper lung lobe contained a large tumor in the region of S1-3; the tumor had shifted to the posterior thoracic space and rotated 90° counterclockwise, potentially impeding blood flow. The patient underwent emergency right upper lobectomy for torsion of the right upper lung lobe. He recovered uneventfully and was discharged without complications.ConclusionsWe experienced a rare case of spontaneous torsion of the right upper lung lobe caused by a large tumor and massive pleural effusion.


Molecular and Clinical Oncology | 2014

Overexpression of G protein‑coupled receptor 87 correlates with poorer tumor differentiation and higher tumor proliferation in non‑small‑cell lung cancer

Kazuhito Nii; Yoshimasa Tokunaga; Dage Liu; Xia Zhang; Jun Nakano; Shinya Ishikawa; Yoshiyuki Kakehi; Reiji Haba; Hiroyasu Yokomise


The Journal of The Japanese Association for Chest Surgery | 2010

Metastatic lung tumor from leiomyosarcoma of the colon: report of a case

Takashi Nakashima; Kazuhito Nii; Taku Okamoto


Journal of Clinical Oncology | 2018

MCL-1 expression of non-small cell lung cancer as a prognostic factor and MCL-1 as a promising target for gene therapy.

Takayuki Nakano; Dage Liu; Nariyasu Nakashima; Hiroyasu Yokomise; Kazuhito Nii; Tetsuhiko Go; Shintaro Tarumi; Sung Soo Chang; Atsushi Fujiwara; Yoshiyuki Kakehi


Journal of Thoracic Oncology | 2017

P3.04-036 Clinical Analysis of the Association between Lung Cancer and Connective Tissue Disease: Topic: Miscellaneous II

Kazuhito Nii; Hiroyasu Yokomise; Tetsuhiko Go; Shintaro Tarumi; Nariyasu Nakashima


Journal of Clinical Oncology | 2017

RRM1 expression is verified as a biomarker predicting the drug sensitivity for GEM with in vitro 3D drug sensitivity test in non-small cell lung cancer tumor.

Nariyasu Nakashima; Dage Liu; Takayuki Nakano; Yusuke Kita; Xia Zhang; Yoshimasa Tokunaga; Shintaro Tarumi; Kazuhito Nii; Tetsuhiko Go; Yoshiyuki Kakehi; Hiroyasu Yokomise


Journal of Clinical Oncology | 2017

Antitumor activity against GPR87-expressing non-small cell lung cancer cells in GPR87-suppressing adenoviral vector.

Takayuki Nakano; Dage Liu; Yusuke Kita; Yoshimasa Tokunaga; Kazuhito Nii; Nariyasu Nakashima; Shintaro Tarumi; Xia Zhang; Tetsuhiko Go; Yoshiyuki Kakehi; Hiroyasu Yokomise


Journal of Clinical Oncology | 2017

Association of tumor-specific GPR87 overexpression with poor prognosis in non-small cell lung cancer.

Kazuhito Nii; Dage Liu; Yoshimasa Tokunaga; Xia Zhang; Shinya Ishikawa; Reiji Haba; Yoshiyuki Kakehi; Hiroyasu Yokomise

Collaboration


Dive into the Kazuhito Nii's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge